365 related articles for article (PubMed ID: 33324406)
1. Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2.
Xiao X; Wang C; Chang D; Wang Y; Dong X; Jiao T; Zhao Z; Ren L; Dela Cruz CS; Sharma L; Lei X; Wang J
Front Immunol; 2020; 11():586572. PubMed ID: 33324406
[TBL] [Abstract][Full Text] [Related]
2. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions.
Bakowski MA; Beutler N; Wolff KC; Kirkpatrick MG; Chen E; Nguyen TH; Riva L; Shaabani N; Parren M; Ricketts J; Gupta AK; Pan K; Kuo P; Fuller M; Garcia E; Teijaro JR; Yang L; Sahoo D; Chi V; Huang E; Vargas N; Roberts AJ; Das S; Ghosh P; Woods AK; Joseph SB; Hull MV; Schultz PG; Burton DR; Chatterjee AK; McNamara CW; Rogers TF
Nat Commun; 2021 Jun; 12(1):3309. PubMed ID: 34083527
[TBL] [Abstract][Full Text] [Related]
3. A high-throughput drug screening strategy against coronaviruses.
Liu J; Li K; Cheng L; Shao J; Yang S; Zhang W; Zhou G; de Vries AAF; Yu Z
Int J Infect Dis; 2021 Feb; 103():300-304. PubMed ID: 33333250
[TBL] [Abstract][Full Text] [Related]
4. A transferable deep learning approach to fast screen potential antiviral drugs against SARS-CoV-2.
Wang S; Sun Q; Xu Y; Pei J; Lai L
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34081143
[TBL] [Abstract][Full Text] [Related]
5. Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19.
Mirabelli C; Wotring JW; Zhang CJ; McCarty SM; Fursmidt R; Pretto CD; Qiao Y; Zhang Y; Frum T; Kadambi NS; Amin AT; O'Meara TR; Spence JR; Huang J; Alysandratos KD; Kotton DN; Handelman SK; Wobus CE; Weatherwax KJ; Mashour GA; O'Meara MJ; Chinnaiyan AM; Sexton JZ
Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34413211
[TBL] [Abstract][Full Text] [Related]
6. Repurposing old drugs as antiviral agents for coronaviruses.
Yang CW; Peng TT; Hsu HY; Lee YZ; Wu SH; Lin WH; Ke YY; Hsu TA; Yeh TK; Huang WZ; Lin JH; Sytwu HK; Chen CT; Lee SJ
Biomed J; 2020 Aug; 43(4):368-374. PubMed ID: 32563698
[TBL] [Abstract][Full Text] [Related]
7. Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV.
Aherfi S; Pradines B; Devaux C; Honore S; Colson P; Scola B; Raoult D
Future Microbiol; 2021 Nov; 16():1341-1370. PubMed ID: 34755538
[TBL] [Abstract][Full Text] [Related]
8. Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL
Jade D; Ayyamperumal S; Tallapaneni V; Joghee Nanjan CM; Barge S; Mohan S; Nanjan MJ
Eur J Pharmacol; 2021 Jun; 901():174082. PubMed ID: 33823185
[TBL] [Abstract][Full Text] [Related]
9. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
10. Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV-2.
Biering SB; Van Dis E; Wehri E; Yamashiro LH; Nguyenla X; Dugast-Darzacq C; Graham TGW; Stroumza JR; Golovkine GR; Roberts AW; Fines DM; Spradlin JN; Ward CC; Bajaj T; Dovala D; Schulze-Gamen U; Bajaj R; Fox DM; Ott M; Murthy N; Nomura DK; Schaletzky J; Stanley SA
ACS Infect Dis; 2021 Aug; 7(8):2337-2351. PubMed ID: 34129317
[TBL] [Abstract][Full Text] [Related]
11. Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors.
Chiou WC; Hsu MS; Chen YT; Yang JM; Tsay YG; Huang HC; Huang C
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):147-153. PubMed ID: 33430659
[TBL] [Abstract][Full Text] [Related]
12. High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors.
Zhao Y; Du X; Duan Y; Pan X; Sun Y; You T; Han L; Jin Z; Shang W; Yu J; Guo H; Liu Q; Wu Y; Peng C; Wang J; Zhu C; Yang X; Yang K; Lei Y; Guddat LW; Xu W; Xiao G; Sun L; Zhang L; Rao Z; Yang H
Protein Cell; 2021 Nov; 12(11):877-888. PubMed ID: 33864621
[TBL] [Abstract][Full Text] [Related]
13. Effective inhibition of coronavirus replication by
Xu H; Li J; Song S; Xiao Z; Chen X; Huang B; Sun M; Su G; Zhou D; Wang G; Hao R; Wang N
Front Biosci (Landmark Ed); 2021 Oct; 26(10):789-798. PubMed ID: 34719206
[No Abstract] [Full Text] [Related]
14. Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection.
Jan JT; Cheng TR; Juang YP; Ma HH; Wu YT; Yang WB; Cheng CW; Chen X; Chou TH; Shie JJ; Cheng WC; Chein RJ; Mao SS; Liang PH; Ma C; Hung SC; Wong CH
Proc Natl Acad Sci U S A; 2021 Feb; 118(5):. PubMed ID: 33452205
[TBL] [Abstract][Full Text] [Related]
15. High-throughput screening of the ReFRAME, Pandemic Box, and COVID Box drug repurposing libraries against SARS-CoV-2 nsp15 endoribonuclease to identify small-molecule inhibitors of viral activity.
Choi R; Zhou M; Shek R; Wilson JW; Tillery L; Craig JK; Salukhe IA; Hickson SE; Kumar N; James RM; Buchko GW; Wu R; Huff S; Nguyen TT; Hurst BL; Cherry S; Barrett LK; Hyde JL; Van Voorhis WC
PLoS One; 2021; 16(4):e0250019. PubMed ID: 33886614
[TBL] [Abstract][Full Text] [Related]
16. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective.
Seifert M; Bera SC; van Nies P; Kirchdoerfer RN; Shannon A; Le TT; Meng X; Xia H; Wood JM; Harris LD; Papini FS; Arnold JJ; Almo S; Grove TL; Shi PY; Xiang Y; Canard B; Depken M; Cameron CE; Dulin D
Elife; 2021 Oct; 10():. PubMed ID: 34617885
[TBL] [Abstract][Full Text] [Related]
18. A Review on Screening Models for Potential Therapeutic Candidates and Targets Against SARS-CoV-2.
Das M; Kumar M; Jha A; Madhukiran DR; Bharti K; Mondal S; Mishra B
Curr Drug Targets; 2021; 22(11):1232-1254. PubMed ID: 33371846
[TBL] [Abstract][Full Text] [Related]
19. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication
Shytaj IL; Fares M; Gallucci L; Lucic B; Tolba MM; Zimmermann L; Adler JM; Xing N; Bushe J; Gruber AD; Ambiel I; Taha Ayoub A; Cortese M; Neufeldt CJ; Stolp B; Sobhy MH; Fathy M; Zhao M; Laketa V; Diaz RS; Sutton RE; Chlanda P; Boulant S; Bartenschlager R; Stanifer ML; Fackler OT; Trimpert J; Savarino A; Lusic M
mBio; 2022 Apr; 13(2):e0370521. PubMed ID: 35229634
[TBL] [Abstract][Full Text] [Related]
20. Identification of SARS-CoV-2 entry inhibitors among already approved drugs.
Yang L; Pei RJ; Li H; Ma XN; Zhou Y; Zhu FH; He PL; Tang W; Zhang YC; Xiong J; Xiao SQ; Tong XK; Zhang B; Zuo JP
Acta Pharmacol Sin; 2021 Aug; 42(8):1347-1353. PubMed ID: 33116249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
